Lipidil

Fenofibrate, the active ingredient in Lipidil, is a fibrate presented as a nanonised oral formulation for oral use. It is employed to lower elevated triglyceride levels and to improve lipid profiles in adults with hypertriglyceridemia or mixed dyslipidemia. It is indicated for patients at risk of pancreatitis due to severe triglyceride elevation and is often part of a comprehensive lipid‑lowering regimen that includes diet and exercise.

GNH USA supplies Lipidil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution.

Fenofibrate is a fibrate that acts on lipid metabolism to modify triglyceride and cholesterol levels. - Hypertriglyceridemia: reduces serum triglyceride concentrations to lower cardiovascular risk. - Mixed dyslipidemia: lowers triglycerides, modestly raises HDL‑cholesterol and reduces LDL‑cholesterol. - Prevention of pancreatitis associated with severe hypertriglyceridemia: decreases the likelihood of pancreatitis by maintaining triglyceride levels within safer limits.

Fenofibrate may cause a range of adverse reactions.

Common Side Effects: - Gastrointestinal upset: nausea, dyspepsia, or abdominal discomfort. - Headache or dizziness. - Myalgia or mild muscle pain.

Serious or Rare Side Effects: - Rhabdomyolysis, especially when combined with statins. - Hepatic dysfunction, indicated by elevated transaminases. - Severe skin reactions such as Stevens‑Johnson syndrome. - Acute pancreatitis. - Renal impairment in susceptible individuals.

Before initiating therapy, consider the following precautions. - Monitor liver function tests: obtain baseline values and repeat periodically. - Assess renal function: adjust or avoid use in severe renal impairment. - Evaluate for gallbladder disease: avoid in patients with active gallstones or biliary obstruction. - Review concomitant statin therapy: increased risk of myopathy requires careful monitoring. - Avoid in patients with known hypersensitivity to fenofibrate or other fibrates. - Store at room temperature: keep in the original container, protect from moisture and light.

Fenofibrate can interact with several drug classes.

Major Interactions (Avoid): - Gemfibrozil: combined use markedly raises the risk of rhabdomyolysis. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase fenofibrate plasma concentrations. - High‑dose statins (especially simvastatin): heightened risk of muscle toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants such as warfarin: fenofibrate may enhance anticoagulant effect and raise INR. - Bile‑acid sequestrants: can reduce fenofibrate absorption, diminishing efficacy. - Oral hypoglycemic agents: fenofibrate may potentiate glucose‑lowering effects, requiring dose adjustment.